|
|
|
| Multimodal Ultrasonographic Analysis of HER-2 Positive Breast Cancer Patients with Different Expression States of Estrogen Receptor and Progesterone Receptor |
| JI Liping, XING Guochen, FENG Peibei, et al |
| Department of Oncology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou Henan 450007 |
|
|
|
|
Abstract 【Objective】To investigate the multimodal ultrasound characteristics of human epidermal growth factor receptor 2 (HER-2) positive breast cancer patients with different expression states of estrogen receptor (ER) and progesterone receptor (PR). 【Methods】A total of 149 patients with HER-2 positive breast cancer admitted to our hospital from May 2020 to March 2024 were selected and divided into group A (n=71, positive HER-2, negative ER and PR), group B (n=27, positive HER-2, positive ER or PR) and group C (n=51, positive ER or PR) according to immunohistochemical results. HER-2, ER, PR positive).Ultrasonic characteristics of HER-2 positive breast cancer patients with different expression states of ER and PR were analyzed. 【Results】The proportion of the group A with unclear boundary, enhanced posterior echo, calcification, mixed internal echo, aspect ratio > 0.7, Adler grade 2-3, and BI-RADS grade 5 was higher than that of the group B and the group C (P<0.05). The above indexes in the group B were higher than those in the group C (P<0.05). The ratio of elasticity score ≥3 and hardness ratio of lesion tissue to adipose tissue in the group A were higher than those in the groups B and C (P<0.05).The above indexes in group B were higher than those in the group C (P<0.05). The peak time (PT) in the group A was shorter than that in the groups B and C (P<0.05), and the PT in group B was shorter than that the in group C (P<0.05). The proportion of enhancement intensity, internal perfusion defect and clear boundary after enhancement in the group A was higher than that in the group B and the group C (P<0.05).The above indexes in group B were higher than those in group C (P<0.05). 【Conclusion】The multimodal ultrasound features of patients with HER-2 positive breast cancer are closely related to the expression of ER and PR.
|
|
Received: 19 February 2025
|
|
|
|
|
|
[1] BURSTEIN H J, SOMERFIELD M R, BARTON D L,et al.Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update[J].J Clin Oncol,2021,39(35):3959-3977.
[2] WANG C, CHE Y. A ultrasonic nomogram of quantitative parameters for diagnosing breast cancer[J].Sci Rep,2023,13(1):12340.
[3] SHAO Y, HASHEMI H S, GORDON P, et al. Breast cancer detection using multimodal time series features from ultrasound shear wave absolute vibro-elastography[J].IEEE J Biomed Health Inform,2022,26(2):704-714.
[4] 中国抗癌协会乳腺癌专业委员会. 中国乳腺癌筛查与早期诊断指南[J].中国癌症杂志,2022,32(4):363-372.
[5] NICOLO E, TARANTINO P, CURIGLIANO G. Biology and treatment of HER2-low breast cancer[J].Hematol Oncol Clin North Am,2023,37(1):117-132.
[6] 岳瑞雪,胡崇珠,郝鑫,等. 曲妥珠单抗和帕妥珠单抗联合不同化疗方案新辅助治疗HER-2阳性乳腺癌真实世界疗效及安全性观察[J].中国肿瘤临床,2023,50(5):248-254.
[7] ZHU J Y, HE H L, JIANG X C, et al. Multimodal ultrasound features of breast cancers: correlation with molecular subtypes[J].BMC Med Imaging,2023,23(1):57.
[8] WU Q, ZHAN Y, WU J F. Multimodal ultrasound features of sclerosing adenosis of the breast: a case report[J].Med Ultrason,2022,24(4):511-512.
[9] ZHANG T Y, TAN T, HAN L Y, et al. Predicting breast cancer types on and beyond molecular level in a multi-modal fashion[J].NPJ Breast Cancer,2023,9(1):16.
[10] WU L Y, ZHAO Y J, LIN P, et al. Preoperative ultrasound radiomics analysis for expression of multiple molecular biomarkers in mass type of breast ductal carcinoma in situ[J].BMC Med Imaging,2021,21(1):84.
[11] 黄贵廉,陈智毅. 乳腺癌超声征象与分子标志物的相关性研究进展[J].中国医学影像学杂志,2021,29(1):86-88.
[12] 冯建丽,马蓉,杨洋,等. 乳腺浸润性导管癌BI-RADS分级与雌激素受体、孕激素受体及人表皮生长因子受体表达的关系[J].海南医学,2021,32(24):3134-3137.
[13] 林子梅,孙杨,高云霞,等. 超声造影定性及定量特征与乳腺癌分子标志物表达的相关性研究[J].中华超声影像学杂志,2021,30(7):569-574. |
|
|
|
2025, Vol. 42 
